Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma.
PD-L1 inhibitor
durvalumab
empyema
lung squamous cell carcinoma
myocarditis
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
01
2022
accepted:
01
06
2022
entrez:
8
7
2022
pubmed:
9
7
2022
medline:
9
7
2022
Statut:
epublish
Résumé
Durvalumab, as a PD-L1 inhibitor, is commonly used for the treatment of various cancers. Adverse events associated with the therapy include hepatitis, nephritis, dermatitis, and myocarditis. Especially, myocarditis as an adverse event after PD-L1 inhibitor therapy is characterized for its low incidence and high mortality. Here we present a rare case of a 67-year-old male with lung squamous cell carcinoma complicated with empyema who experienced myocarditis after only PD-L1 inhibitor durvalumab monotherapy. He presented with markedly decrease left ventricular ejection fraction, elevated Natriuretic peptide BNP, Troponin T, Troponin I, ESR, CRP and interleukin-6. The electrocardiogram showed sinus tachycardia, low voltage of limb leads, T wave inversion in anterior waves and V1-V3 QS type. Myocardial injury occurred in a short period and quickly returned to normal after glucocorticoids therapy. This case report is of clinical value for the treatment of PD-L1 related myocarditis.
Sections du résumé
Background
UNASSIGNED
Durvalumab, as a PD-L1 inhibitor, is commonly used for the treatment of various cancers. Adverse events associated with the therapy include hepatitis, nephritis, dermatitis, and myocarditis. Especially, myocarditis as an adverse event after PD-L1 inhibitor therapy is characterized for its low incidence and high mortality.
Case Summary
UNASSIGNED
Here we present a rare case of a 67-year-old male with lung squamous cell carcinoma complicated with empyema who experienced myocarditis after only PD-L1 inhibitor durvalumab monotherapy. He presented with markedly decrease left ventricular ejection fraction, elevated Natriuretic peptide BNP, Troponin T, Troponin I, ESR, CRP and interleukin-6. The electrocardiogram showed sinus tachycardia, low voltage of limb leads, T wave inversion in anterior waves and V1-V3 QS type. Myocardial injury occurred in a short period and quickly returned to normal after glucocorticoids therapy.
Conclusion
UNASSIGNED
This case report is of clinical value for the treatment of PD-L1 related myocarditis.
Identifiants
pubmed: 35801208
doi: 10.3389/fmed.2022.866068
pmc: PMC9253414
doi:
Types de publication
Case Reports
Langues
eng
Pagination
866068Informations de copyright
Copyright © 2022 Zhou, Li, Chen and She.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancers (Basel). 2022 Feb 23;14(5):
pubmed: 35267453
J Am Coll Cardiol. 2019 Oct 1;74(13):1714-1727
pubmed: 31558256
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
JAMA Oncol. 2019 Nov 1;5(11):1635-1637
pubmed: 31436802
Cardiovasc Res. 2019 Apr 15;115(5):854-868
pubmed: 30715219
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
Front Immunol. 2021 Nov 16;12:786046
pubmed: 34868071
Circulation. 2021 Nov 2;144(18):1521-1523
pubmed: 34723640
J Am Heart Assoc. 2020 Jan 21;9(2):e013757
pubmed: 31960755
Front Oncol. 2021 Nov 25;11:757993
pubmed: 34900707
Intern Med. 2022 Feb 15;61(4):527-531
pubmed: 34433717
Front Pharmacol. 2021 Nov 12;12:710943
pubmed: 34867321
BMJ. 2020 Apr 6;369:m736
pubmed: 32253223
Circulation. 2018 Aug 14;138(7):743-745
pubmed: 30359135
N Engl J Med. 2021 Jun 10;384(23):2229-2240
pubmed: 34107182
Front Oncol. 2021 Nov 10;11:763527
pubmed: 34900711
Brain Behav Immun. 1996 Dec;10(4):337-50
pubmed: 9045749